Marker Therapeutics, Inc. (MRKR) SEC Filings — 2024
19 SEC filings for Marker Therapeutics, Inc. (MRKR) in 2024.
Filings
- Marker Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Dec 23, 2024
- Marker Therapeutics Files 8-K: Material Agreement, Other Events — 8-K · Dec 19, 2024
- Marker Therapeutics Sells Subsidiary — 8-K · Dec 17, 2024
- Marker Therapeutics Files 8-K on Financials — 8-K · Nov 14, 2024
- Marker Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 14, 2024
- Marker Therapeutics Files 8-K on Financials — 8-K · Aug 14, 2024
- Marker Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 14, 2024
- Marker Therapeutics Sells Subsidiary, Focuses on T-cell Therapies — 8-K · Aug 12, 2024
- Marker Therapeutics Sells Subsidiary to Lenders — 8-K · Jun 12, 2024
- NEA 16 Amends Stake in Marker Therapeutics — SC 13D/A · May 17, 2024
- Marker Therapeutics Files 8-K on Financials — 8-K · May 15, 2024
- Marker Therapeutics Q1 2024 Update — 10-Q · May 15, 2024
- Marker Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024
- Marker Therapeutics Files 8-K — 8-K · Apr 8, 2024
- Marker Therapeutics Sells Subsidiary to Catalent for $1B — 8-K · Mar 26, 2024
- Marker Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 26, 2024
- Marker Therapeutics Terminates Material Definitive Agreement — 8-K · Mar 1, 2024
- Marker Therapeutics Enters Material Definitive Agreement — 8-K · Feb 26, 2024
- MRKR Files 8-K on Jan 8, Signals Corporate Communications Activity — 8-K · Jan 8, 2024